

## SUPPLEMENTAL INFORMATION

### **Zinc-dependent multimerization of mutant calreticulin is required for MPL binding and MPN pathogenesis**

Jeanne F Rivera<sup>1,2,11</sup>, April J Baral<sup>1,11</sup>, Fatima Nadat<sup>1</sup>, Grace Boyd<sup>3</sup>, Hershna Patel<sup>4</sup>, Rachael Smyth<sup>1</sup>, Emma L Burman<sup>1</sup>, Ghadah Alameer<sup>1</sup>, Sally A Boxall<sup>1</sup>, Brian R Jackson<sup>1</sup>, E. Joanna Baxter<sup>5</sup>, Peter Laslo<sup>2</sup>, Anthony R Green<sup>5,6,7</sup>, David G. Kent<sup>3</sup>, Ann Mullally<sup>8,9,10</sup>, Edwin Chen<sup>1,4</sup>

<sup>1</sup>School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, LS2 9JT, United Kingdom.

<sup>2</sup>Division of Haematology and Immunology, Leeds Institute for Medical Research, St. James's University Hospital, University of Leeds, Leeds, LS9 7TF, United Kingdom.

<sup>3</sup>Department of Biology, University of York, York, YO10 5DD, United Kingdom.

<sup>4</sup>School of Life Sciences, University of Westminster, London, W1W 6UW, United Kingdom.

<sup>5</sup>Department of Hematology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, United Kingdom.

<sup>6</sup>Wellcome MRC Cambridge Stem Cell Institute, University of Cambridge, Hills Road, Cambridge, CB2 0XY, United Kingdom.

<sup>7</sup>Department of Hematology, University of Cambridge, CB2 0XY, United Kingdom.


<sup>8</sup>Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.

<sup>9</sup>Broad Institute, 415 Main Street, Cambridge, Massachusetts 02142, USA.

<sup>10</sup>Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.


<sup>11</sup>These authors contributed equally to this work.

**Figure S1**




**Supplemental Figure S1. Loss of H42 does not affect CALR<sup>del52</sup> activity. (A)** Growth curves in Ba/F3-MPL cells expressing CALR<sup>del52</sup> variants harboring loss of histidine-42 (H42) alone or in combination with H99, H145 or H170. **(B-C)** Intracellular phosphorylation flow cytometry (Panel B) and immunoblotting (Panel C) demonstrate robust Stat3 and Stat5 phosphorylation in of Ba/F3-MPL cells expressing CALR<sup>del52</sup> variants harboring loss of H42 alone or in combination with H99, H145 or H170. Numbers in red indicate ratio of mean fluorescence intensity for each sample relative to isotype control.

**Figure S2**




**Supplemental Figure S2. Quantitation of CALR<sup>del52</sup> and MPL co-localization by FRET.** Representative confocal images of 293T cells expressing MPL-GFP fusion protein (green), mCherry-fused histidine-deficient CALR<sup>del52</sup> variants fused to mCherry fluorophore (red) and areas of signal overlap (yellow). Quantitation of energy transfer by FRET are denoted in pseudocolour (magenta).

**Figure S3**




**Supplemental Figure S3. TPEN abrogates CALR<sup>del52</sup>-induced JAK-STAT signaling in Ba/F3-MPL cells.** Intracellular phosphorylation flow cytometry demonstrate decreased Stat5 (Panel A) and Stat3 (Panel B) phosphorylation in Ba/F3-MPL cells in CALR<sup>del52</sup> variants following treatment of TPEN for 4 hours. Numbers in red indicate ratio of mean fluorescence intensity for each sample relative to isotype control. The data are representative of 2 independent experiments.

**Figure S4**



**Supplemental Figure S4. TPEN abrogation of JAK-STAT signaling correlates with decreased levels of intracellular zinc. (A)** Zinquin staining quantitation of free intracellular zinc levels in TPEN-treated CALR<sup>del52</sup> and MPL<sup>W515L</sup> Ba/F3 cells by flow cytometry. **(B)** Correlation between zinquin mean fluorescence intensity (MFI) and TPEN dosage reveals similar extent of zinc chelation in both CALR<sup>del52</sup> and MPL<sup>W515L</sup> Ba/F3 cells. **(C)** Correlation between zinquin MFI and pSTAT3/5 MFI reveals strong correlation between zinc chelation and STAT3/5 signaling in CALR<sup>del52</sup>-expressing Ba/F3-MPL cells and weaker correlation in Ba/F3-MPL<sup>W515L</sup> Ba/F3 cells.

**Figure S5**



**Supplemental Figure S5. TPEN abrogates CALR<sup>del52</sup>-induced JAK-STAT signaling in UT7-MPL cells.** **(A)** Viability of UT7-MPL cells expressing CALR<sup>del52</sup> or MPL<sup>W515L</sup> following treatment with TPEN for 48 hours. Cell viability was quantified by MTT assays. Each point represents the mean of three independent cultures. The data is representative of at least 2 independent experiments. Testing for statistical significance was performed using a student's t-test (\*: p<0.05). **(B)** FLAG-pulldown assays demonstrating TPEN treatment disrupts CALR<sup>del52</sup>-MPL binding in UT7-MPL cells. **(C)** Immunoblotting demonstrates decreased Stat3 and Stat5 phosphorylation status following TPEN treatment in CALR<sup>del52</sup>-expressing UT7-MPL cells but not in UT7-MPL<sup>W515L</sup> cells.